Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials.
about
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryCongestive heart failure and diabetes mellitus: balancing glycemic control with heart failure improvementRole of estrogen in diastolic dysfunctionFemale-specific aspects in the pharmacotherapy of chronic cardiovascular diseasesDifferences in efficacy and safety of pharmaceutical treatments between men and women: an umbrella reviewEffects of treatment with zofenopril in men and women with acute myocardial infarction: gender analysis of the SMILE ProgramSex differences in cardiovascular disease - Impact on care and outcomes.Therapy insight: heart disease and the insulin-resistant patient.Diabetic cardiovascular disease: getting to the heart of the matter.Primary care-based multifaceted, interdisciplinary medical educational intervention for patients with systolic heart failure: lessons learned from a cluster randomised controlled trialAgeing-related cardiomyocyte functional decline is sex and angiotensin II dependentRationale, design and conduct of a randomised controlled trial evaluating a primary care-based complex intervention to improve the quality of life of heart failure patients: HICMan (Heidelberg Integrated Case Management).Effects of β-blockers on all-cause mortality in patients with type 2 diabetes and coronary heart diseaseTreatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research DatabaseSex-specific mortality differences in heart failure patients with ischemia receiving cardiac resynchronization therapy.Comparative effectiveness research in heart failure therapies: women, elderly patients, and patients with kidney diseaseSex and gender differences in myocarditis and dilated cardiomyopathySex differences in type 2 diabetes: focus on disease course and outcomesGaps in Medical and Device Therapy for Patients with Left Ventricular Systolic Dysfunction: The EchoGap Study.Emerging clinical applications in cardiovascular pharmacogenomics.Implications of the angiotensin converting enzyme gene insertion/deletion polymorphism in health and disease: a snapshot review.Characterization of the cardiac renin angiotensin system in oophorectomized and estrogen-replete mRen2.Lewis rats.Race and association of angiotensin converting enzyme/angiotensin receptor blocker exposure with outcome in heart failure.Molecular Mechanisms of Retinoid Receptors in Diabetes-Induced Cardiac Remodeling.Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial.Angiotensin II receptor blockers in older patients.Association of β-blocker exposure with outcomes in heart failure differs between African American and white patients.Multivariate Meta-Analysis of Heterogeneous Studies Using Only Summary Statistics: Efficiency and Robustness.Sex-specific association of age with carotid artery distensibility: multi-ethnic study of atherosclerosisThe use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure.Barriers to guideline implementation and educational needs of general practitioners regarding heart failure: a qualitative study.Coronary heart disease prevention in menopausal women.Cardioprotection: the role of beta-blocker therapy.Out-patient management of chronic heart failure.Ambulatory hemodynamics in patients with chronic heart failure: implications for volume management in elderly patients.Isosorbide dinitrate and hydralazine hydrochloride: a review of efficacy and safety.Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management.The effectiveness of beta-blockers in women with congestive heart failure.Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approachesThe timing hypothesis and hormone replacement therapy: a paradigm shift in the primary prevention of coronary heart disease in women. Part 1: comparison of therapeutic efficacy.
P2860
Q22241786-277036AD-6A19-4179-B4E8-157AD25B24E4Q27003819-88BAF9B1-C73C-45A9-A5FA-D1CD1CB964FAQ27026798-977C471E-4337-4CB8-B263-C789F5564425Q28182631-9626DE79-BB42-4173-9654-0972CBD71D94Q28474985-D68BE2EF-8945-46BB-92F2-25FBF63B38FDQ28544671-E3225F68-1D7A-4D02-89E5-5FC624F193F3Q30234726-EFF74D9C-3F9F-4525-B4C1-B47B755A1CAAQ30351748-AF788F8D-87FB-4E54-8348-D0646DD062F1Q30451529-A543199D-050C-4159-B589-7933C4B094AAQ30489956-20ADB587-4E09-4E52-9956-A22414E37F03Q30582755-EDD79957-7C7E-403D-AEFD-98B6669E0ED2Q33294995-0C774B7B-B834-497F-A7CE-4F9C1830607FQ33834187-821C9CCE-6AE4-440E-9575-B4EA0D396B29Q33873040-EC8AF899-E293-4DE3-9076-1F77611F317AQ33880742-A2E03E9F-FEC2-41F8-B1D9-04FB5AEDD2BDQ34017388-29239067-4CCE-4FF3-B004-B81F457DFD8CQ34060039-CE9A5842-1302-4756-A702-FA4B7341EF2CQ34229975-84FBE9F8-9C9E-4BC7-BE72-E7E184BEC74EQ34384769-BE4A82C7-0EB8-474E-977B-CE5A55F14987Q34400491-7AA484AA-5CD8-4DF0-9C3F-13752015DB8CQ34793905-D05465B6-F4C0-4D33-B654-1DC6E05C45A4Q35034941-89CC0403-D6BB-4977-8794-BD8DF7EA910BQ35088348-787E403A-9B7A-4FC4-87E1-2E1F491096A4Q35667311-1FA22FE8-8603-4E03-9470-B4C17C0071E0Q35759370-59EE4C2B-A7D4-432A-94EB-551D5E011FEEQ35843149-86B6D773-0AB9-4653-BFC7-FE657A82C313Q35848432-6CD01C54-584F-4F13-99EA-56149E3E061BQ35857159-0E8AB238-B452-4367-A1C3-A1D7AE64BF34Q35965156-095BEBA7-4F02-4A6E-8191-0A18DD3C85B0Q36013015-4C802EBE-1779-4FCD-A41D-D4F5F4CC450FQ36028715-6F717D00-3F43-477A-AAD7-FCDE44FCB478Q36150753-1E3228F0-7163-4687-949E-986936D5C1E1Q36193234-DE3B4D8F-3311-4E44-95A9-D9244EA436A0Q36249926-BA1E1295-F384-4646-A540-8EF3E8717855Q36296067-1B87A9C6-4E04-402B-BB71-22BE415D72E3Q36314825-8E818FD6-C74C-4031-AD69-EED9A1E7EDC8Q36383373-3190C591-E94B-49B3-BB43-2FFA9379CF7CQ36416666-3B745409-4FAE-476B-8CC3-D0407C4AC11EQ36608474-95871FE1-642B-4D3D-BD3F-8190A2DE6AD1Q36863876-F8341C54-6450-4E98-87AB-8B3D35250A88
P2860
Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Efficacy of angiotensin-conver ...... ysis of major clinical trials.
@ast
Efficacy of angiotensin-conver ...... ysis of major clinical trials.
@en
Efficacy of angiotensin-conver ...... ysis of major clinical trials.
@nl
type
label
Efficacy of angiotensin-conver ...... ysis of major clinical trials.
@ast
Efficacy of angiotensin-conver ...... ysis of major clinical trials.
@en
Efficacy of angiotensin-conver ...... ysis of major clinical trials.
@nl
prefLabel
Efficacy of angiotensin-conver ...... ysis of major clinical trials.
@ast
Efficacy of angiotensin-conver ...... ysis of major clinical trials.
@en
Efficacy of angiotensin-conver ...... ysis of major clinical trials.
@nl
P2093
P1476
Efficacy of angiotensin-conver ...... ysis of major clinical trials.
@en
P2093
Anthony Steimle
Barry Greenberg
Col Sid W Atkinson
Lynne Warner Stevenson
Margaret Maglione
Marvin A Konstam
Michael Barrett
Michael W Rich
Paul G Shekelle
Sally C Morton
P304
P356
10.1016/S0735-1097(03)00262-6
P407
P577
2003-05-01T00:00:00Z